Diminished noradrenergic stimulation reduces the activity of rolipram-sensitive, high-affinity cyclic AMP phosphodiesterase in rat cerebral cortex

Journal of Neurochemistry

Volumn 66, Issue 5, 1996, Pages 1894-1902

  Ye, Ying ^a,b   O'Donnell, James M ^a  

^a LOUISIANA STATE UNIV MEDICAL CENTER   (United States)

^b Louisiana State University Health Sciences Center at Shreveport   (United States)

Author keywords

6 Hydroxydopamine; Cyclic AMP hydrolysis; Noradrenergic system; Phosphodiesterase; Propranolol; Rolipram

Indexed keywords

BETA ADRENERGIC RECEPTOR; CYCLIC AMP; CYCLIC AMP PHOSPHODIESTERASE; NEUROTRANSMITTER RECEPTOR; PHOSPHODIESTERASE; ROLIPRAM;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN CORTEX; ENZYME ACTIVITY; HYDROLYSIS; MALE; NONHUMAN; NORADRENERGIC SYSTEM; PRIORITY JOURNAL; RAT; RECEPTOR BLOCKING; REGULATORY MECHANISM;

3',5'-CYCLIC-NUCLEOTIDE PHOSPHODIESTERASE; ANIMALS; BINDING, COMPETITIVE; CEREBRAL CORTEX; CYCLIC AMP; DOSE-RESPONSE RELATIONSHIP, DRUG; HYDROLYSIS; INJECTIONS, INTRAVENTRICULAR; ISOPROTERENOL; MALE; NOREPINEPHRINE; OXIDOPAMINE; PHOSPHODIESTERASE INHIBITORS; PROPRANOLOL; PYRROLIDINONES; RATS; RATS, SPRAGUE-DAWLEY; ROLIPRAM;

ANIMALIA;

EID: 0029923241     PISSN: 00223042     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1471-4159.1996.66051894.x     Document Type: Article

References (41)

1. Alvarez R., Sette C., Yang D., Eglen R. M., Wilhelm R., Shelton E. R., and Conti M. (1995) Activation and selective inhibition of a cyclic AMP-specific phosphodiesterase, PDE-4D3. Mol. Pharmacol. 48, 616-622.
2. Barber R. and Butcher R. W. (1988) cAMP turnover in intact cells, in Methods in Enzymology, Vol. 159 (Corbin J. D. and Johnson R. A., eds), pp. 50-60. Academic Press, New York.
3. Barber R., Goka T. J., and Butcher R. W. (1992) Cyclic AMP turnover in intact tissue: role of cyclic nucleotide phosphodiesterases. Adv. Second Messenger Phosphoprotein Res. 25, 1-11.
4. Beavo J. A., Conti M., and Heaslip R. J. (1994) Multiple cyclic nucleotide phosphodiesterases. Mol. Pharmacol. 46, 399-405.
5. Bradford M. M. (1976) A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal. Biochem. 72, 248-254.
6. Browning E. T., Brostrom C. B., and Groppi V. E. Jr. (1976) Altered adenosine cyclic 3′,5′-monophosphate synthesis and degradation by C-6 astrocytoma cells following prolonged exposure to norepinephrine. Mol. Pharmacol. 12, 32-40.
7. Challiss R. A. and Nicholson C. D. (1990) Effects of selective phosphodiesterase inhibition on cyclic AMP hydrolysis in rat cerebral cortical slices. Br. J. Pharmacol. 99, 47-52.
8. Conti M., Toscano M. V., Geremia P. R., and Stefanini M. (1982) Regulation by follicle-stimulating hormone and dibutyryl adenosine 3′,5′-monophosphate of a phosphodiesterase isoenzyme of the Sertoli cell. Endocrinology 110, 1189-1196.
9. Conti M., Kasson B. G., and Hsueh A. J. W (1984) Hormonal regulation of 3′,5′-adenosine monophosphate phosphodiesterases in cultured rat granulosa cells. Endocrinology 114, 2361-2367.
10. D'Armiento M., Johnson G. S., and Pastan I. (1972) Regulation of adenosine 3′,5′-cyclic monophosphate phosphodiesterase activity in fibroblasts by intracellular concentrations of cyclic adenosine monophosphate. Proc. Natl. Acad. Sci. USA 69, 459-462.
11. Eison L. S., Yocca F. D., and Gianutsos G. (1988) Noradrenergic denervation alters serotonin2-mediated behavior but not serotonin2 receptor number in rats: modulatory role of beta adrenergic receptors. J. Pharmacol. Exp. Ther. 246, 571-577.
12. Engels P., Fichtel K., and Lubbert H. (1994) Expression and regulation of human and rat phosphodiesterase type IV isogenes. FEBS Lett. 350, 291-295.
13. Fleischhacker W. W., Hinterhuber H., Bauer H., Pflug B., Berner P., Simhandl C., Wolf R., Gerlach W., Jaklitsch H., Sastre-y-Hernandez M., Schmeding-Wiegel H., Sperner-Unterweger B., Voet B., and Schubert H. (1992) A multicenter double-blind study of three different doses of the new cAMP-phosphodiesterase inhibitor rolipram in patients with major depressive disorder. Neuropsychobiology 26, 59-64.
14. Kehr W., Debus G., and Neumeister R. (1985) Effects of rolipram, a novel antidepressant, on monoamine metabolism in rat brain. J. Neural Transm. 63, 1-12.
15. Maganiello V. and Vaughan M. (1972) Prostaglandin E1 effects on adenosine 3′,5′-cyclic monophosphate concentration and phosphodiesterase activity in fibroblasts. Proc. Natl. Acad. Sci. USA 69, 269-273.
16. Moyer J. A., Greenberg L. H., Frazer A., and Weiss B. (1980) Subsensitivity of the beta-adrenergic receptor-linked adenylate cyclase system of rat pineal gland following repeated treatment with desmethylimipramine and nialamide. Mol. Pharmacol. 19, 187-193
17. Mukai J., Asai T., Naka M., and Tanaka T. (1994) Separation and characterization of a novel isoenzyme of cyclic nucleotide phosphodiesterase from rat cerebrum. Br. J. Pharmacol. 111, 389-390.
18. Nicholson C. D., Jackman S. A., and Wilke R (1989) The ability of denbufylline to inhibit cyclic nucleotide phosphodiesterase and its affinity for adenosine receptors and the adenosine reuptake site. Br. J. Pharmacol. 97, 889-897.
19. O'Donnell J. M. (1990) Behavioral effects of beta adrenergic agonists and antidepressant drugs after down-regulation of beta-2 adrenergic receptors by clenbuterol. J. Pharmacol. Exp. Ther. 254, 147-154.
20. O'Donnell J. M. (1993) Antidepressant-like effects of rolipram and other inhibitors of cyclic AMP phosphodiesterase on behavior maintained by differential reinforcement of low response rate. J. Pharmacol. Exp. Ther 264, 1168-1178.
21. O'Donnell J. M. and Frazer A. (1985) Effects of clenbuterol and antidepressant drugs on beta adrenergic receptor/N-protein coupling in the cerebral cortex of the rat. J Pharmacol. Exp. Ther. 234, 30-36.
22. O'Donnell J. M. and Seiden L. S. (1983) Altered effects of desipramine on operant performance after 6-hydroxydopamine-induced depletion of brain dopamine or norepinephrine. J. Pharmacol. Exp. Ther. 229, 629-635.
23. O'Donnell J. M., Frith S., and Wilkins J. (1994) Involvement of beta-1 and beta-2 adrenergic receptors in the antidepressant-like effects of centrally administered isoproterenol. J. Pharmacol. Exp Ther. 271, 246-254.
24. Oleshansky M. A. and Neff N. H. (1975) Rat pineal adenosine cyclic 3′,5′-monophosphate phosphodiesterase activity: modulation in vivo by a beta adrenergic receptor. Mol. Pharmacol. 11, 552-557.
25. Schmiechen R., Schneider H. H., and Wachtel H. (1990) Close correlation between behavioral response and binding in vivo for inhibitors of the rolipram-sensitive phosphodiesterase. Psychopharmacology (Berl.) 102, 17-20.
26. Schneider H. H., Schmiechen R., Brezinski M., and Seidler J. (1986) Stereospecific binding of the antidepressant rolipram to brain protein structures. Eur. J. Pharmacol. 127, 105-115.
27. Schneider H. H., Yamaguchi M., Andrew J. S., and Stephens D. N. (1995) Discriminative stimulus properties of the stereoisomers of the phosphodiesterase inhibitor rolipram. Pharmacol. Biochem. Behav. 50, 211-217.
28. Schoeffter P. and Stoclet J. C. (1990) Age-related differences in cyclic AMP metabolism and their consequences on relaxation induced by isoproterenol and phosphodiesterase inhibitors in rat isolated aorta. Mech. Ageing Dev. 54, 197-205.
29. Schultz J. E. and Schmidt B. H. (1986) Rolipram, a stereospecific inhibitor of calmodulin-independent phosphodiesterase, causes β-adrenoceptor subsensitivity in rat cerebral cortex. Naunyn Schmiedebergs Arch. Pharmacol. 333, 23-30.
30. Sette C., Iona S., and Conti M. (1994a) The short-term activation of a rolipram-sensitive, cAMP specific-phosphodiesterase by thyroid-stimulating hormone in thyroid FRTL-5 cells is mediated by a cAMP-dependent phosphorylation. J. Biol. Chem. 269, 9245-9252.
31. Sette C., Vicini E., and Conti M. (1994b) The ratPDE3/IVd phosphodiesterase gene codes for multiple proteins differentially activated by cAMP-dependent protein kinase. J. Biol. Chem. 269, 18271-18274.
32. Sporn J. R., Wolfe B. B., Harden T. K., and Molinoff P. B. (1977) Supersensitivity in rat cerebral cortex: pre- and post-synaptic effects of 6-hydroxydopamine at noradrenergic synapses. Mol. Pharmacol. 13, 1170-1180.
33. Stanley C., Brown A. M., and Hill S. J. (1989) Effect of isozyme-selective inhibitors of phosphodiesterase on histamine-stimulated cyclic AMP accumulation in guinea-pig hippocampus. J. Neurochem. 52, 671-676.
34. Swinnen J. V., Joseph D. R., and Conti M. (1989) The mRNA encoding a high-affinity cAMP phosphodiesterase is regulated by hormones and cAMP. Proc. Natl. Acad. Sci. USA 86, 8197-8201.
35. Thompson W. J. and Appleman M. M. (1970) Multiple cyclic nucleotide phosphodiesterase activities from rat brain. Biochemistry 10, 311-316.
36. Torphy T. J., Zhou H. L., and Cieslinski L. B. (1992) Stimulation of beta adrenoceptors in a human monocyte cell line (U937) up-regulates cyclic AMP-specific phosphodiesterase activity. J. Pharmacol. Exp. Ther. 263, 1195-1205.
37. Uzunov P., Shein H. M., and Weiss B. (1973) Cyclic AMP phosphodiesterase in cloned astrocytoma cells: norepinephrine induces a specific enzyme form. Science 180, 304-306.
38. Wachtel H. (1983) Potential antidepressant activity of rolipram and other selective adenosine 3′,5′-monophosphate phosphodiesterase inhibitors. Neuropharmacology 22, 267-272.
39. Wachtel H. (1988) Defective second-messenger function in the etiology of endogenous depression: novel therapeutic approaches, in New Concepts in Depression (Briley M. and Fillion G., eds), pp. 227-293. Macmilian Press, London.
40. Wachtel H. and Schneider H. H. (1986) Rolipram, a novel antidepressant drug, reverses the hypothermia and hypokinesia of monoamine-depleted mice by an action beyond postsynaptic monoamine receptors. Neuropharmacology 25, 1119-1126.
41. Whalin M. E., Garrett R. L., Thompson W. J., and Strada S. J. (1989) Correlation of cell-free brain cyclic nucleotide phosphodiesterase activities to cyclic AMP decay in intact brain slices. Second Messengers Phosphoproteins 12, 311-325.